Biotech investing can feel a little bit like a Vegas sportsbook sometimes. Pick the company with the right drug trial and you ...

Over one million federal workers didn't get paid during the government shutdown. Members of Congress did. Here's how much they made.

If you are looking to generate a large income stream, these two ETFs pair up nicely to give you yield and the opportunity for ...

However, given the nature of its investments (i.e., speculative bonds issued by companies with fragile financial positions), ...

XLP has performed better and has a lower expense ratio, but RSPS isn't as dependent on its top stocks to succeed.

After returning 17.5% during the first 10 months of 2025, with dividends reinvested, the S&P 500 index has declined modestly so far in November. But a closer look at the sectors and individual stocks ...

The investment seeks to provide investors with returns that match the price return of the SPDR® S&P 500® ETF Trust up to a predetermined upside cap while seeking to maximize the downside protection ...

Nobel winner Paul Krugman explains why Trump's policies are "going badly" and making life less affordable for Americans.

The recent pullback for big techs in the U.S. underscores the need for investors to focus more on international stocks and ...

Explore how FLRN ETF offers low duration risk and variable rates amid shifting Fed policy and inflation trends.

Dr. Richard Pazdur is “likely the best possible person for the role,” says one analyst. A calmer course for the FDA could add fuel to the recent run-up in biotech stocks.